πŸ‡ΊπŸ‡Έ FDA
Patent

US 10076505

Inhalation formulations of Treprostinil

granted A61KA61K31/19A61K31/191

Quick answer

US patent 10076505 (Inhalation formulations of Treprostinil) held by United Therapeutics Corporation expires Mon Sep 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
United Therapeutics Corporation
Grant date
Tue Sep 18 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K31/19, A61K31/191, A61K31/192, A61K31/201